CA2785228A1 - Pharmaceutical composition with antimicrobial activity for parenteral administration and process for preparing same - Google Patents

Pharmaceutical composition with antimicrobial activity for parenteral administration and process for preparing same Download PDF

Info

Publication number
CA2785228A1
CA2785228A1 CA2785228A CA2785228A CA2785228A1 CA 2785228 A1 CA2785228 A1 CA 2785228A1 CA 2785228 A CA2785228 A CA 2785228A CA 2785228 A CA2785228 A CA 2785228A CA 2785228 A1 CA2785228 A1 CA 2785228A1
Authority
CA
Canada
Prior art keywords
parenteral administration
pharmaceutical composition
silicon dioxide
weight
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2785228A
Other languages
French (fr)
Inventor
Viktor Lvovich Limonov
Konstantin Valentinovich Gaidul
Aleksandr Valerevich Dushkin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2785228A1 publication Critical patent/CA2785228A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to pharmacology, medicine, veterinary medicine and to the pharmaceutical industry, in particular to a process for preparing original composite antimicrobial preparations for parenteral administration which have increased therapeutic effectiveness in the treatment of severe forms of infectious and inflammatory diseases. The proposed pharmaceutical compositions comprise, as active ingredient, beta-lactam antibiotics and highly disperse nanostructured silicon dioxide in ratios of from 10:1 to 75:1 by weight, respectively. The silicon dioxide particles present in the composition are the means of supplying the molecules of the antibiotics to the phagocytes, which makes it possible to increase, in a targeted manner, the concentration of the antimicrobial preparations in the areas of inflammation and to substantially neutralize the phenomenon of antibiotic resistance of microorganisms. The claimed process for preparing a pharmaceutical composition consists in mixing a beta-lactam antibiotic substance with highly disperse nanostructured silicon dioxide and is characterized in that the mixture of the above-mentioned substances in ratios of from 10:1 to 75:1 by weight, respectively, is subjected to mechanical processing by means of impact abrasion until the proportion by weight of the finely disperse fraction (< 5 µm) is increased to at least 25%. The resultant mixture is used for preparing injection solutions.

Claims (4)

1. Antimicrobial pharmaceutical composition for parenteral administration containing betalactam antibiotic as therapeutic agent. Its' main difference is that it is made as an injections preparation powder and contains finely dispersed nanostructured silica dioxide and betalactam antibiotic in weight ratio (10-75): 1.
2. The composition according to claim 1, is different by its' finely dispersed nanostructured silica dioxide particles (their dimension is less than 5 micron) portion, which is not less than 25%.
3. The production process of the antimicrobial pharmaceutical composition for parenteral administration includes mixing betalactam antibiotic with other components is noted by the fact that powder like betalactam antibiotic is mixed with powder like finely dispersed nanostructured silica dioxide in weight ratio (10-75):1. The received mixture is mechanized impact abrasive actions.
4. The production process according to claim 3, different by mechanized impact abrasive actions, makes the finely dispersed nanostructured silica dioxide particles quantity (with less than 5 micron dimension) not less than 25%.
CA2785228A 2010-09-13 2011-05-11 Pharmaceutical composition with antimicrobial activity for parenteral administration and process for preparing same Abandoned CA2785228A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
RU201001449 2010-09-13
EA201001449A EA021874B1 (en) 2010-09-13 2010-09-13 Pharmaceutical composition with antimicrobial activity for parenteral administration and process for preparing same
PCT/RU2011/000320 WO2012036585A1 (en) 2010-09-13 2011-05-11 Pharmaceutical composition with antimicrobial activity for parenteral administration and process for preparing same

Publications (1)

Publication Number Publication Date
CA2785228A1 true CA2785228A1 (en) 2012-03-22

Family

ID=45908207

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2785228A Abandoned CA2785228A1 (en) 2010-09-13 2011-05-11 Pharmaceutical composition with antimicrobial activity for parenteral administration and process for preparing same

Country Status (9)

Country Link
JP (1) JP2013537190A (en)
CN (1) CN103096896A (en)
AU (1) AU2011302724C1 (en)
BR (1) BR112012023964A2 (en)
CA (1) CA2785228A1 (en)
EA (1) EA021874B1 (en)
MX (1) MX2012010535A (en)
NZ (1) NZ598831A (en)
WO (1) WO2012036585A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125214A0 (en) * 1996-02-29 1999-03-12 Fujisawa Pharmaceutical Co Beta-lactam antibiotic-containing tablet and method for producing the same
JP2010500340A (en) * 2006-08-11 2010-01-07 パナセア バイオテック リミテッド Particles for delivering active ingredients, methods for their production and compositions
RU2377985C2 (en) 2006-12-25 2010-01-10 Сергей Михайлович Юдин Preparation for treating infectious diseases caused by multiresistant bacteria

Also Published As

Publication number Publication date
JP2013537190A (en) 2013-09-30
EA201001449A1 (en) 2012-02-28
AU2011302724B2 (en) 2012-06-28
AU2011302724A1 (en) 2012-05-03
CN103096896A (en) 2013-05-08
WO2012036585A1 (en) 2012-03-22
AU2011302724C1 (en) 2012-11-29
MX2012010535A (en) 2012-11-16
WO2012036585A8 (en) 2012-10-04
BR112012023964A2 (en) 2016-08-02
NZ598831A (en) 2013-11-29
EA021874B1 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
SG196818A1 (en) Processes and compositions for liposomal and efficient delivery of gene silencing therapeutics
WO2011042463A3 (en) Pharmaceutical composition comprising poorly soluble active ingredient and hyperbranched polymer
WO2012039642A8 (en) Pharmaceutical composition having antimicrobial and fast-healing activity for external administration, process for preparing same
CA2785228A1 (en) Pharmaceutical composition with antimicrobial activity for parenteral administration and process for preparing same
AU2012211402B2 (en) Pharmaceutical composition for the preparation of infusion solutions of antimicrobial preparations, its&#39; production process
CN102600081B (en) Amoxicillin and clavulanate potassium injection and preparation method thereof
UA103118C2 (en) Pharmaceutical composition with antimicrobial activity for parenteral administration and process for preparing same
UA103116C2 (en) Powder-like pharmaceutical parenteral composition having antimicrobial and anti-inflammatory activity and comprising fosfomicin and fine nanostructured silicon dioxide, process for preparing same
CN105456268A (en) Compound pharmaceutical composition containing piperacillin sodium and tazobactam sodium and preparation method of compound pharmaceutical composition
EA201100733A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUBERCULOSIS AND OTHER INFECTIONS, THE METHOD OF ITS PREPARATION
KR101092599B1 (en) Antibiotic complex formulation for animal use
NZ601748B (en) Pharmaceutical composition for the preparation of infusion solutions of antimicrobial preparations, its&#39; production process
CN102406612A (en) Potassium clavulanate soluble powder and preparation method thereof
EA201100736A1 (en) PHARMACEUTICAL COMPOSITION OF ANTIMICROBIAL ACTION FOR PARENTERAL APPLICATION

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20150512